Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
“Besides individual investors there’s also brokerages that are interested in new biotech startups as well granted most can’t get in this low and many others can’t even invest in the otc.”
Better this way for us loading now!
Bingo
Lol ok
April is a big month. Phase 2 gy testing, fda meeting, ide draft update, new certification training for isopet clinic, Mayo Clinic running there test setup…
IMO
Mid to late May/June submission of final IDE
IMO
June/July FDA Approval
IMO
July/September phase 1 human starts
CONTAINED!
Sticky this
Welcome aboard. Not a stock in the world setup the way this one is about to explode. However am conservative to say near term should definitely put us between .30-.60
Agreed 100%
It’s Saturday already ladies and gentlemen
But but the dotted trajectory line on the little red paper airplane is go up :)
Exubrion is a private company? Merger?
https://www.hopkinsmedicine.org/news/articles/radiopharmaceutical-therapy-in-veterinary-patients
Within the past two years, two new radiopharmaceuticals have been approved for therapeutic purposes in veterinary medicine: yttrium-90 (hydrogel solution) and tin-117m (colloid solution).
Krimins uses Y-90 hydrogel therapy to treat solid cutaneous malignant tumors. It can also be used inside the body following removal of an intra-cavitary malignant tumor to ensure all cancer cells are eradicated. The radioactive material is prepared and administered for each patient individually based on the type and location of the cancer and other factors. The Y-90 hydrogel is injected into the tumor at 5 millimeter spacings. Therapy is outpatient; animals can go home the same day as treatment. This newer radiopharmaceutical is not excreted, and it does not migrate or irradiate healthy tissue, Krimins noted. Post-treatment, owners are advised to limit prolonged direct contact between humans (especially children and pregnant women) and the treated tissue for several weeks following treatment to limit any potential exposure.
In her research, Krimins offers several case studies of patients treated for malignancy with Y-90 hydrogel. Francis, an 11-year-old Yorkshire terrier, had a cancerous high-grade soft tissue sarcoma removed, but still had signs of cancer around the edges of removed tissues (known as dirty margins). Since his treatment in January 2022, Francis is thriving and remains cancer-free. Oliver, a 12-year-old domestic shorthair cat, had a fibrosarcoma in a limb. The limb was amputated, but the fibrosarcoma grew back at the amputation site. Oliver was treated twice with Y-90 hydrogel, most recently in July 2022, with no tumor recurrence to date.
Agree as while the tweets can be a bit much at times it does shed light on near term indicators of positive things to come. However if it’s quite for to long then concern will set in. By no means are we close to that yet but March was a long month and it has been crickets. The only thing to come to light was cfo selling 16,000 shares for under $1,000. I’m not looking for a submission pr but definitely something that says we are on the way. I am also not looking for negative long term set back PRs either. Slowly and steady and keep churning.
I was wrong about tweet week. Crickets
Like button
Nah, not really. Skt just seems to reply to everyone all the time with his opinionated facts. We all just keeping it real the way skt wants it.
Well by that logic, he has 31 days to wait so it doesn’t become a wash sale then can repurchase. Which if that is the case hopefully that means we are within 2 months of submitting and getting approval.
While insignificant wonder why the interim CFO sold his only shares of 16k for less then $1000. Wonder if they are cleaning up there internal stakeholders to prepare for something much bigger
Lol ??
Tweet week
Your opinions are not facts
Wrong
To include that’s a 15x on SHPH which if RDGL had that type of move then that .98 at that 15x multiple. Going back to my original prediction imo I think it’s fair and conservative
I think it’s very conservative, absolutely no way to know how high and for how long.
Over .50 with submission
Over $1.00 with approval
Over $1.50 with phase 1 start
Over $2.50 with phase 1 pass
All imo
So do the math
Shoot. $5-$10 will not be until after fda approval for humans so maybe within the next 24 months. Have to get through rabbits, ide approval, clinical human trials, phase 1 and 2 then we will see those numbers.
However imo a large spike can occur and then settle sooner then later.
Personally I do feel pet test are a catalyst to approval just my opinion
If it’s a newbie playing an fda play then they wouldn’t be scared off by any means on pet testing providing they do their due diligence on how strong of a position rdgl is in. If they are playing it as a single interest of it being an fda play they will get in and sell on approval pop. Period.
Longs will persevere and rdgl will prove all neigh-sayers wrong
Been here 5 plus years and have witnessed the significant improvements, patents, debt repayments, positive results from pet patients, training modules for new vets, etc. the list goes on and on. Dollar land soon
According to you there are no catalysts yet everyone else on this board thinks otherwise so for what it’s worth I’d say not looking good for your opinion. If pet test aren’t the catalyst for approval then I don’t know what is. You can’t say the catalyst is after approval.
Time is relative. First step is ide which has a high probability of approval. Then Mayo getting their test done and into trials for thyroid cancer which was the best indication to start with before advancing into the other 17 indications. This thing is primed for success. Providing no additional set backs rdgl time is now and will soon be one of the top tools in the toolbox
Sounds like a winner then. All else is mute . Get approval ide, then fda approval then game over rdgl wins
But if radiogel can knock out the tumor reducing the amount of beam radiation needed to knock out the microscopic areas then they would compliment each other therefore increasing market usage for what radiogel would be used for
15 days until next big update give or take a day or two
2.5 weeks before next big update. Get your shares NOW
Yeah RDGL will fly past .30 since when it hit that high last time we were just in the unknown thought of FDA approval. This time we have been hand held by the FDA and certainty of approval has sky rocketed in confidence. .30 will possibly be $3.00 soon enough now. IMHO
That’s what I said earlier but someone said I was wrong
So either business practices change and vet/hospitals use isopet/radiogel for the better of mankind and pps goes up OR major buyout happens and isopet/radiogel gets shelved and pps goes up on buyout.
Either way is good for me regarding financials but I’d hope mankind will benefit from this technology and it not be shelved